NS Pharma, Inc.
NS-229
Eosinophilic Granulomatosis With Polyangiitis
Countdown
177days
Phase 2 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 2 trial results for NS-229 in Eosinophilic Granulomatosis With Polyangiitis are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06046222: Phase 2 trial, sponsor NS Pharma, Inc., drug NS-229. Primary completion date 2026-12 (estimated).”